Chris Goss
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Chris Goss sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Chris Goss: 6 sponsored US clinical trials, 3 recruiting.
Chris Goss sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis Pulmonary Exacerbation, with 1 trials.
Upper-quartile sponsor footprint
Chris Goss sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
NCT07312734
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Observational Study Comparing Home to Office Spirometry
NCT05285410
Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
NCT03801993
Standardized Treatment of Pulmonary Exacerbations II
NCT02781610
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
Where Chris Goss enrollment is open (later-stage tilt)
3 recruiting of 6 indexed (50% open); 3 completed (50%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Cystic Fibrosis Pulmonary Exacerbation (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Chris Goss: open-pipeline peers nationwide
Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Chris Goss sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Chris Goss page
6 registered trials is a research-attention snapshot, not an endorsement of Chris Goss or any single study.
- 3 of Chris Goss's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis Pulmonary Exacerbation is the condition Chris Goss studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis Pulmonary Exacerbation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Chris Goss pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.